Leveraging its integrated “design-synthesis-quality control” system, Creative Biolabs is overcoming bottlenecks in mRNA drug expression and in vivo stability ...

RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the cost-intensive in vitro transcription (IVT) step. Join this webinar to ...

In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new vaccines has become crucial. However, the speed of vaccine production is ...

With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is hindered by its production ...

RIO RANCHO, N.M.--(BUSINESS WIRE)--Nature’s Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, today launched NTx Services. This new service ...

mRNA innovation is one of the most exciting and impactful areas of healthcare globally today. A process that has increasingly expansive application potential in treating diseases or functioning as a ...

RNA came to prominence during COVID-19 with mRNA vaccines saving millions of lives worldwide. Since then, the technology has evolved with some developers now focusing on personalized mRNA therapeutics ...

From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

Add Yahoo as a preferred source to see more of our stories on Google. New AI model predicts mRNA protein output, aiding drug and vaccine design by targeting specific cells. (CREDIT: Science Photo ...

STOCKHOLM--(BUSINESS WIRE)--At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5' ...

Stay ahead in the booming mRNA market, projected to reach $63.28 billion by 2025, with the 3 rd mRNA Process Development & Manufacturing Summit 2025 - Europe’s premier industry-focused forum dedicated ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. WASHINGTON (AP) — So-called mRNA vaccines ...